Last reviewed · How we verify

COVID-19 mRNA vaccine — Competitive Intelligence Brief

COVID-19 mRNA vaccine (COVID-19 mRNA vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

COVID-19 mRNA vaccine (COVID-19 mRNA vaccine) — Vaccine Company, Inc.. The vaccine delivers mRNA encoding the SARS-CoV-2 spike protein, which is translated by host cells to trigger adaptive immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
COVID-19 mRNA vaccine TARGET COVID-19 mRNA vaccine Vaccine Company, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation mRNA-1273 Variant-containing Formulation ModernaTX, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific)
Pfizer-COVID-19 Vaccine Pfizer-COVID-19 Vaccine National Heart, Lung, and Blood Institute (NHLBI) marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
Spikevax bivalent Original/Omicron BA.1 Spikevax bivalent Original/Omicron BA.1 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
BioNTech - Pfizer COVID-19 vaccine BioNTech - Pfizer COVID-19 vaccine University of Birmingham marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1273 mRNA-1273 Assistance Publique - Hôpitaux de Paris marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
bivalent BNT162b2 (original/Omi BA.4/BA.5) bivalent-bnt162b2-original-omi-ba-4-ba-5 Pfizer marketed mRNA vaccine SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COVID-19 mRNA vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/covid-19-mrna-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: